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eply
e appreciate these insightful comments on our paper (1) and
ully agree that mitral regurgitation can importantly contribute to
he development of pulmonary hypertension in left-sided heart
ailure. As demonstrated in heart failure with reduced ejection
raction (2,3), hemodynamically significant mitral regurgitation
an cause left atrial volume and pressure overload with resultant
ncreases in pulmonary artery systolic pressure independent of left
entricular filling pressures. As noted in the Methods section (1),
n our sample of heart failure with preserved ejection fraction
HFpEF), patients with hemodynamically significant (greater than
oderate) mitral regurgitation were excluded in accordance with
merican College of Cardiology/American Heart Association
uidelines for the diagnosis of HFpEF (4). In our hypertensive
ontrol group from the general community, clinically significant
itral valve disease was exceedingly rare (n  2, 0.4%). Thus, we
onclude that mitral regurgitation at rest did not contribute to the
evelopment of pulmonary hypertension in our sample.
One could speculate that hemodynamic stress during periods of
ypertension or exercise could produce intermittent mitral regurgita-
ion and contribute to the development of pulmonary hypertension.
owever, we excluded patients with intrinsic valve disease (mitral
alve prolapse, and so on) who would be susceptible to stress-induced
orsening of mitral regurgitation. Further, in contrast to heart failure
ith reduced ejection fraction, the lack of ventricular dilation in
FpEF would make it unlikely for significant “functional” mitral
egurgitation to develop. We did not exclude patients with coronary
rtery disease, which could cause ischemic mitral regurgitation with
tress. Hence, while we agree that mitral regurgitation can contribute
o pulmonary hypertension in heart failure patients, it would seem
nlikely to be a major contributor in this cohort.
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y Atrial Natriuretic Peptide
an It Work?
e congratulate Morikawa et al. (1) on this important paper on
herapeutic prevention of contrast-induced nephropathy, and
hen (2) for his editorial comment putting this research into
erspective. The editorial comment already mentioned many
ositive aspects of the study.
Contrast-induced nephropathy frequently complicates primary
ercutaneous coronary intervention (3). In the present study,
orikawa et al. (1) chose an intermediate dose of atrial natriuretic
eptide (ANP) at 0.042 g/kg/min to prevent contrast-induced
ephropathy and found—corresponding with the physiological
ffect of “natriuretic” peptide—increased diuresis associated with a
tatistically significant but clinically perhaps not meaningful
hange of glomerular markers (serum creatinine, estimated glo-
erular filtration rate, cystatin C) at 1 month after the procedure
ompared with control, for example, a reduced loss of estimated
lomerular filtration rate 1 ml/min/1.73 m2. The relevance of
his finding is further questioned by the lack of an effect of ANP
n markers of tubular damage (urinary microglobulin and
-acetyl-D-glucosaminidase), although contrast-induced ne-
hropathy has been described involving tubular damage.
A previous randomized controlled trial using nesiritide pre-
ented during the Congress of the American Society of Nephrol-
gy 2008 (4) showed an absolute reduction in the incidence of
cute kidney injury after cardiac surgery similar to that of the
resent study (1), but although powered for it, the former study
ould not demonstrate a reduced need for dialysis and was
iscontinued after an interim analysis (4).
It would strengthen the message further to discuss why, in the
tudy by Morikawa et al. (1), N-acetylcysteine has not been used
or nephroprotection although N-acetylcysteine has been shown to
educe the incidence of contrast-induced nephropathy and the
ortality associated with it (5,6). N-acetylcysteine does not arti-
cially reduce serum creatinine concentration (7), which was a
revious concern (8), and its use is current clinical practice for
atients undergoing angiography who present with chronic kidney
isease at many European centers.
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September 22, 2009:1190–4Last, patients of the present study were hospitalized for at least
8 h after the procedure, which deviates from clinical practice, at
east in the U.S. and in Europe—the additional potential risks
thrombosis, infection) and costs need to be considered.
We hope that the authors can further elucidate the issue of 272
atients assessed for eligibility, with only 4 patients who did not fulfill
he inclusion criteria (serum creatinine 1.3 mg/dl), suggesting that
lmost all patients presenting for angiography at this hospital have
hronic renal impairment with an average estimated glomerular
ltration rate of 30 ml/min/1.73 m2. Additional comment on this
ssue may provide more complete insight into the local patient
opulation.
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eply
ontrast-induced nephropathy (CIN) involves both glomerular fil-
ration failure and tubular dysfunction. However, CIN is defined only
sing the value of serum creatinine, or estimated glomerular filtration
ate (eGFR) calculated from serum creatinine (1). Creatinine and
ystatin C are endogenous markers of glomerular filtration, and all of
hem are contained in blood. By contrast, tubular dysfunction
arkers such as N-acetyl--D-glucosaminidase (NAG) and  -1
nd 2-microglobulin are collected from urine. A few reportsegarding CIN estimated NAG and microglobulin (2). These
eports showed that the markers of glomerular filtration failure
eem to be more appropriate as CIN markers than tubular
ysfunction markers, even if they were expressed after being
djusted by dividing by urine creatinine. We could not adjust the
alues of NAG and microglobulin by urine creatinine (3). This
ay be the reason that we detected no significant difference in
AG and 2-microglobulin. In our results, 2-microglobulin was
ignificantly higher at 24 h from baseline in both atrial natriuretic
eptide (ANP) and control groups (both p  0.0001). In all
atients combined, the decrease in eGFR was1 ml/min/1.73 m2
s pointed out, but the decrease in 19 patients with CIN was 9.1
l/min/1.73 m2 at 48 h.
In our study, only 1 patient in the control group required
emporary dialysis. The long-term prognosis with treatment
ith ANP or nesiritide (B-type natriuretic peptide) should be
stimated in a large, controlled multicenter study. In an integrated
dvanced algorithm for the management of CIN, treatment with
-acetylcysteine or ascorbic acid as an antioxidant is recom-
ended in the case of eGFR in the range of 30 to 59 ml/min (1),
ut an analysis of studies using N-acetylcysteine demonstrated that
ignificant benefits were observed in only one-half of the studies in
atients with chronic renal insufficiency (4). As the algorithm
ays, adjunctive medications do not require all patients to
ndergo angiography—only the subjects already with renal
nsufficiency. If the number of patients with CIN were reduced
o one-fourth by ANP as demonstrated in our study, the cost
ould be negligible.
We used Ringer solution containing 28 mEq for hydration
ithout bicarbonate because volume supplementation with either
ntravenous normal saline or bicarbonate remains a better regimen
or preventing CIN in moderate- to high-risk patients (1,5). We
hould pay more attention to high-risk patients with renal insuf-
ciency during angiography. We recruited 272 patients with
reatinine levels of 1.3 and 6 mg/dl, but excluded 11 before
reatment was assigned, and 4 of them showed creatinine levels
utside of the acceptable range.
Finally, we suggest again that in addition to hydration, treat-
ent with a dose of ANP infusion that is calibrated so as not to
educe blood pressure too greatly helps to prevent CIN.
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